<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41937">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01984424</url>
  </required_header>
  <id_info>
    <org_study_id>20120332</org_study_id>
    <nct_id>NCT01984424</nct_id>
  </id_info>
  <brief_title>Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3</brief_title>
  <official_title>A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Evolocumab, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor Due to Muscle Related Side Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <authority>Netherlands: Centrale Commissie Mensgebonden Onderzoek (CCMO)</authority>
    <authority>Norway: Norwegian Medicines Agency (Statens legemiddelverk)</authority>
    <authority>Czech Republic: State Institute for Drug Control (SUKL)</authority>
    <authority>Italy: National Monitoring Centre for Clinical Trials - Ministry of Health</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>Germany: Paul-Ehrlich-Institute</authority>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <authority>South Africa: Medicines Control Council</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Canada: Health Canada</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is divided into 3 parts (A, B, C). Part A is a double-blind, placebo-controlled,
      two-period cross-over rechallenge of atorvastatin 20 mg. Part B is a 24-week double-blind,
      double-dummy comparison of evolocumab and ezetimibe. Part C is a 2-year open-label
      evolocumab extension. The primary hypothesis is that evolocumab will be well tolerated and
      will result in greater reduction of LDL-C than ezetimibe, defined by the mean percent change
      from baseline at Weeks 22 and 24 of Part B and percent change from baseline at Week 24 of
      Part B, in statin-intolerant hypercholesterolemic subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean percent change from baseline in low density lipoprotein-cholesterol</measure>
    <time_frame>22 and 24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percent change from baseline in low density lipoprotein-cholesterol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change from baseline in low density lipoprotein-cholesterol</measure>
    <time_frame>24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change from baseline in low density lipoprotein-cholesterol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in low density lipoprotein-cholesterol</measure>
    <time_frame>22 and 24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean change from baseline in low density lipoprotein-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in low density lipoprotein-cholesterol</measure>
    <time_frame>24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in low density lipoprotein-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean low density lipoprotein-cholesterol response (low density lipoprotein-cholesterol &lt; 70 mg/dL [1.8 mmol/L])</measure>
    <time_frame>22 and 24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean low density lipoprotein-cholesterol response (low density lipoprotein-cholesterol &lt; 70 mg/dL [1.8 mmol/L])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low density lipoprotein-cholesterol response (low density lipoprotein-cholesterol &lt; 70 mg/dL [1.8 mmol/L])</measure>
    <time_frame>24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Low density lipoprotein-cholesterol response (low density lipoprotein-cholesterol &lt; 70 mg/dL [1.8 mmol/L])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in total cholesterol</measure>
    <time_frame>22 and 24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percent change from baseline in total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in total cholesterol</measure>
    <time_frame>24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change from baseline in total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in non-high density lipoprotein-cholesterol</measure>
    <time_frame>22 and 24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percent change from baseline in non-high density lipoprotein-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in non-high density lipoprotein-cholesterol</measure>
    <time_frame>24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change from baseline in non-high density lipoprotein-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in apolipoprotein B</measure>
    <time_frame>22 and 24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percent change from baseline in apolipoprotein B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in apolipoprotein B</measure>
    <time_frame>24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change from baseline in apolipoprotein B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in the total cholesterol/high density lipoprotein-cholesterol ratio</measure>
    <time_frame>22 and 24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percent change from baseline in the total cholesterol/high density lipoprotein-cholesterol ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in the total cholesterol/high density lipoprotein-cholesterol ratio</measure>
    <time_frame>24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change from baseline in the total cholesterol/high density lipoprotein-cholesterol ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in apolipoprotein B/apolipoprotein A1 ratio</measure>
    <time_frame>22 and 24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percent change from baseline in apolipoprotein B/apolipoprotein A1 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in apolipoprotein B/apolipoprotein A1 ratio</measure>
    <time_frame>24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change from baseline in apolipoprotein B/apolipoprotein A1 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in lipoprotein (a)</measure>
    <time_frame>22 and 24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percent change from baseline in lipoprotein (a)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in lipoprotein (a)</measure>
    <time_frame>24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change from baseline in lipoprotein (a)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in triglycerides</measure>
    <time_frame>22 and 24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percent change from baseline in triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in triglycerides</measure>
    <time_frame>24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change from baseline in triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in high density lipoprotein-cholesterol</measure>
    <time_frame>22 and 24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percent change from baseline in high density lipoprotein-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in high density lipoprotein-cholesterol</measure>
    <time_frame>24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change from baseline in high density lipoprotein-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in very low density lipoprotein-cholesterol</measure>
    <time_frame>22 and 24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percent change from baseline in very low density lipoprotein-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in very low density lipoprotein-cholesterol</measure>
    <time_frame>24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change from baseline in very low density lipoprotein-cholesterol</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Part A (two-period cross-over), Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A (two-period cross-over), Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evolocumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ezetimbe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C, Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evolocumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part A, Atorvastatin</intervention_name>
    <description>Subjects will receive atorvastatin daily</description>
    <arm_group_label>Part A (two-period cross-over), Arm 1</arm_group_label>
    <arm_group_label>Part A (two-period cross-over), Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Part A, Placebo (administered orally)</intervention_name>
    <description>Subjects will receive oral placebo daily</description>
    <arm_group_label>Part A (two-period cross-over), Arm 1</arm_group_label>
    <arm_group_label>Part A (two-period cross-over), Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part B, Evolocumab</intervention_name>
    <description>Subjects will receive subcutaneous evolocumab every month</description>
    <arm_group_label>Part B, Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Part B, Placebo (administered orally)</intervention_name>
    <description>Subjects will receive oral placebo every day</description>
    <arm_group_label>Part B, Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part B, Ezetimibe</intervention_name>
    <description>Subjects will receive oral ezetimibe daily</description>
    <arm_group_label>Part B, Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Part B, Placebo (administered subcutaneously)</intervention_name>
    <description>Subjects will receive subcutaneous placebo every month.</description>
    <arm_group_label>Part B, Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part C, Evolocumab</intervention_name>
    <description>Subjects will receive subcutaneous evolocumab every 2 weeks or monthly</description>
    <arm_group_label>Part C, Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥ 18 to ≤ 80 years of age

          -  Subject not at LDL-C goal

          -  History of statin intolerance

          -  Lipid lowering therapy has been stable prior to enrolment for at least 4 weeks

          -  Fasting triglycerides ≤ 400 mg/dL

        Exclusion Criteria:

          -  NYHA III or IV heart failure

          -  Uncontrolled cardiac arrhythmia

          -  Uncontrolled hypertension

          -  Type 1 diabetes

          -  Poorly controlled type 2 diabetes

          -  Uncontrolled hypothyroidism or hyperthyroidism
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92648</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sterling</city>
        <state>Illinois</state>
        <zip>61081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2015</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ashford</city>
        <state>South Australia</state>
        <zip>5035</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 0B2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St-Charles-Borromee</city>
        <state>Quebec</state>
        <zip>J6E 6J2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4M6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 4</city>
        <zip>140 21</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>München</city>
        <zip>80638</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oslo</city>
        <zip>0373</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ålesund</city>
        <zip>6003</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 8TA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>November 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High Cholesterol, Treatment for high cholesterol, Lowering cholesterol, Lowering high cholesterol, Hypercholesterolemia</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
